BC017643 Activators
Glucocorticoid Receptor Activators are a varied group of compounds primarily consisting of natural and synthetic glucocorticoids, which bind to and activate the Glucocorticoid Receptor (GR), a pivotal protein in the regulation of immune response and metabolism. Naturally occurring cortisol and the synthetic analog hydrocortisone directly engage with the GR, causing a conformational alteration that facilitates the receptor's translocation into the nucleus and subsequently modulates gene transcription. Synthetic glucocorticoids like dexamethasone, prednisolone, and betamethasone have a higher affinity for the GR compared to cortisol, resulting in a more pronounced activation of the receptor and stronger transcriptional responses. These activators enhance the GR's ability to regulate genes that are crucial in controlling inflammation and immune function, making them powerful agents in managing conditions involving excessive inflammatory responses.
BC017643 Activators encompass a collection of chemical compounds that can indirectly stimulate the functional activity of BC017643 through various signaling pathways. Forskolin and Isoproterenol both augment intracellular cAMP levels, which could lead to activation of PKA, a kinase that phosphorylates a multitude of proteins. If BC017643 is a substrate for PKA, its activity could be enhanced through this pathway. PMA and Ionomycin, acting as activators of PKC and calcium-dependent protein kinases respectively, have the potential to phosphorylate BC017643 if it possesses serine, threonine, or calcium-sensitive domains, thereby influencing its activity. Similarly, LY294002 and Wortmannin, as PI3K inhibitors, and EGCG as a kinase inhibitor, could potentially modify the phosphorylation status of BC017643, resulting in enhanced activity if BC017643 is negatively regulated by kinases downstream of PI3K or is subject to inhibitory phosphorylation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which phosphorylates serine and threonine residues on target proteins. If BC017643 has such residues that are critical for its activity, PKC activation could lead to enhanced BC017643 function. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium concentrations, potentially activating calcium-dependent protein kinases. These kinases could then phosphorylate BC017643, enhancing its activity if BC017643 is sensitive to calcium signaling. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is known to inhibit certain protein kinases, which could relieve inhibitory phosphorylation on BC017643, thereby enhancing its activity if BC017643 is regulated by such inhibitory phosphorylation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can alter signaling pathways downstream of PI3K, including Akt signaling. If BC017643 activity is suppressed by Akt-mediated phosphorylation, inhibition of PI3K could enhance BC017643 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that leads to alterations in Akt signaling. Similar to LY294002, if BC017643 is negatively regulated by Akt, Wortmannin could lead to its activation. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 is a calcium ionophore that increases intracellular calcium levels, potentially activating calcium/calmodulin-dependent kinases that could enhance BC017643 activity if it is regulated by calcium signaling. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, leading to increased cAMP levels, which could enhance BC017643 activity through cAMP-dependent protein kinase pathways if BC017643 is part of this signaling process. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $103.00 $245.00 | 8 | |
Zaprinast inhibits phosphodiesterase types 5 and 6, increasing cGMP levels, which can activate PKG pathways. If BC017643 is a substrate for PKG or is regulated by cGMP-dependent signaling, zaprinast could enhance its activity. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram inhibits phosphodiesterase type 4, leading to increased cAMP levels, which may activate PKA and could enhance the activity of BC017643 if it is part of the cAMP-dependent signaling cascade. | ||||||